|
GB1463520A
(en)
*
|
1974-09-06 |
1977-02-02 |
Pfizer Ltd |
Process for the production of imidazolines
|
|
JPS5373571A
(en)
*
|
1976-12-10 |
1978-06-30 |
Otsuka Pharmaceut Co Ltd |
Carbostyril derivatives
|
|
JPS542338A
(en)
|
1977-04-22 |
1979-01-09 |
Sandoz Ag |
Pharmaceutical composition
|
|
US4188393A
(en)
|
1977-04-22 |
1980-02-12 |
Sandoz Ltd. |
Treating spastic conditions or relaxing muscles
|
|
FR2449087A2
(fr)
*
|
1979-02-16 |
1980-09-12 |
Rhone Poulenc Ind |
Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
|
|
US4486432A
(en)
*
|
1982-09-30 |
1984-12-04 |
Eli Lilly And Company |
Quinoxalinedione leukotriene release inhibitors
|
|
FR2541680B1
(fr)
*
|
1983-02-24 |
1985-06-14 |
Rhone Poulenc Sante |
Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
|
|
GB8827820D0
(en)
*
|
1988-11-29 |
1988-12-29 |
Janssen Pharmaceutica Nv |
(1h-azol-1-ylmethyl)substituted quinoline derivatives
|
|
US5180721A
(en)
*
|
1989-05-22 |
1993-01-19 |
Allergan, Inc. |
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
|
|
US5281591A
(en)
*
|
1989-05-22 |
1994-01-25 |
Allergan, Inc. |
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
|
|
US5198442A
(en)
*
|
1989-10-12 |
1993-03-30 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
|
|
US5231096A
(en)
*
|
1989-10-12 |
1993-07-27 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
US5112822A
(en)
*
|
1989-10-12 |
1992-05-12 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
|
|
US5326763A
(en)
*
|
1989-10-12 |
1994-07-05 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
US5077292A
(en)
*
|
1989-10-12 |
1991-12-31 |
Allergan, Inc. |
(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
|
|
US5204347A
(en)
*
|
1989-10-12 |
1993-04-20 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
|
|
US5021416A
(en)
*
|
1989-10-31 |
1991-06-04 |
Allergan, Inc. |
Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
|
|
US5215991A
(en)
*
|
1990-01-26 |
1993-06-01 |
Allergan, Inc. |
Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
|
|
US5130441A
(en)
*
|
1990-02-06 |
1992-07-14 |
Allergan, Inc. |
Method for producing amino-2-imidazoline derivatives
|
|
US5237072A
(en)
*
|
1990-02-06 |
1993-08-17 |
Allergan, Inc. |
Method for producing amino-2-imidazoline derivatives
|
|
US5252595A
(en)
*
|
1990-02-28 |
1993-10-12 |
Allergan, Inc. |
Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
|
|
US5091528A
(en)
*
|
1990-09-12 |
1992-02-25 |
Allergan, Inc. |
6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
|
|
US6323204B1
(en)
*
|
1993-10-13 |
2001-11-27 |
Allergan |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
AU688380B2
(en)
*
|
1993-10-13 |
1998-03-12 |
Allergan, Inc. |
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
|
|
US5580892A
(en)
*
|
1993-10-22 |
1996-12-03 |
Allergan |
Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
|
|
US5578607A
(en)
*
|
1993-12-17 |
1996-11-26 |
The Procter & Gamble Company |
6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
|
|
PT736020E
(pt)
*
|
1993-12-17 |
2000-10-31 |
Procter & Gamble |
Compostos 6-(2-imidazolinilamino)quinolina uteis como alfa-2 adrenoceptor agonistas
|
|
US5576437A
(en)
*
|
1993-12-17 |
1996-11-19 |
The Procter & Gamble Company |
7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
|
|
CN1137755A
(zh)
*
|
1993-12-17 |
1996-12-11 |
普罗克特和甘保尔公司 |
用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物
|
|
US5478858A
(en)
*
|
1993-12-17 |
1995-12-26 |
The Procter & Gamble Company |
5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
|
|
CA2158763C
(en)
*
|
1994-02-08 |
2002-10-29 |
David R. Pierce |
Novel process for preparation of clonidine derivatives
|
|
EP0775134A4
(en)
|
1994-08-04 |
1997-08-13 |
Synaptic Pharma Corp |
NEW BENZIMIDAZOLE DERIVATIVES
|
|
US6294563B1
(en)
|
1994-10-27 |
2001-09-25 |
Allergan Sales, Inc. |
Combinations of prostaglandins and brimonidine or derivatives thereof
|
|
US6194415B1
(en)
*
|
1995-06-28 |
2001-02-27 |
Allergan Sales, Inc. |
Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
|
|
US5916900A
(en)
|
1995-06-29 |
1999-06-29 |
The Procter & Gamble Company |
7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
|
|
ID22812A
(id)
*
|
1996-11-25 |
1999-12-09 |
Procter & Gamble |
Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2
|
|
US6172095B1
(en)
|
1996-11-25 |
2001-01-09 |
The Procter & Gamble Company |
Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
|
WO1998023612A1
(en)
*
|
1996-11-25 |
1998-06-04 |
The Procter & Gamble Company |
2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
|
|
US6306877B1
(en)
|
1999-08-09 |
2001-10-23 |
The Procter & Gamble Co. |
Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
|
KR20000069128A
(ko)
*
|
1996-11-25 |
2000-11-25 |
데이비드 엠 모이어 |
알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물
|
|
AU730369B2
(en)
|
1996-11-25 |
2001-03-08 |
Board Of Regents Of The University Of Nebraska, The |
Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
|
|
US6495583B1
(en)
|
1997-03-25 |
2002-12-17 |
Synaptic Pharmaceutical Corporation |
Benzimidazole derivatives
|
|
ES2223143T3
(es)
|
1997-11-24 |
2005-02-16 |
THE PROCTER & GAMBLE COMPANY |
Derivados de 5-(2-imidazolinilamino)-bencimidazol, preparacion y uso de los mismos como agonistas de adrenorreceptores alfa con estabilidad metabolica mejorada.
|
|
WO2004073708A1
(en)
|
1998-12-17 |
2004-09-02 |
Dean Thomas R |
Brinzolamide and brimonidine for treating ocular conditions
|
|
US20040214829A1
(en)
*
|
2000-07-14 |
2004-10-28 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
US8858961B2
(en)
*
|
2000-07-14 |
2014-10-14 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
WO2002005853A2
(en)
|
2000-07-14 |
2002-01-24 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
US20050026924A1
(en)
*
|
2000-07-14 |
2005-02-03 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
|
CN1441679A
(zh)
*
|
2000-07-14 |
2003-09-10 |
阿勒根公司 |
包含具有提高的溶解度的治疗活性组分的组合物
|
|
DE10161767A1
(de)
*
|
2001-12-15 |
2003-06-26 |
Merck Patent Gmbh |
2-Guanidino-4-heterocyclyl-chinazoline
|
|
US7642258B2
(en)
*
|
2002-04-19 |
2010-01-05 |
Allergan, Inc. |
Combination of brimonidine and timolol for topical ophthalmic use
|
|
US7030149B2
(en)
*
|
2002-04-19 |
2006-04-18 |
Allergan, Inc. |
Combination of brimonidine timolol for topical ophthalmic use
|
|
EP1549305B1
(en)
*
|
2002-10-08 |
2009-04-22 |
Allergan, Inc. |
Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of morbus alzheimer and morbus parkinson
|
|
HK1080408B
(en)
*
|
2002-10-08 |
2008-08-08 |
Allergan, Inc. |
Use of brimonidine in the treatment of dementia and parkinsons disease
|
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
|
US8410102B2
(en)
|
2003-05-27 |
2013-04-02 |
Galderma Laboratories Inc. |
Methods and compositions for treating or preventing erythema
|
|
US7439241B2
(en)
|
2003-05-27 |
2008-10-21 |
Galderma Laboratories, Inc. |
Compounds, formulations, and methods for treating or preventing rosacea
|
|
DE602004023516D1
(de)
|
2003-08-07 |
2009-11-19 |
Allergan Inc |
Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
|
|
KR100953246B1
(ko)
*
|
2003-08-14 |
2010-04-16 |
어레이 바이오파마 인크. |
수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
WO2005039567A1
(en)
*
|
2003-10-08 |
2005-05-06 |
Allergan, Inc. |
Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
|
|
MXPA06013649A
(es)
|
2004-05-25 |
2007-07-09 |
Sansrosa Pharmaceutical Dev In |
Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
|
|
US7534795B2
(en)
*
|
2005-10-25 |
2009-05-19 |
Allergan, Inc. |
Compounds and their use related to compositions for treating disease
|
|
US8067433B2
(en)
|
2005-11-09 |
2011-11-29 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of ophthalmic disorders
|
|
DE602006009968D1
(de)
|
2005-11-15 |
2009-12-03 |
Array Biopharma Inc |
N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
|
|
WO2008074068A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Prana Biotechnology Limited |
Substituted quinoline derivatives as antiamyloidogeneic agents
|
|
WO2008144399A1
(en)
*
|
2007-05-18 |
2008-11-27 |
Bausch & Lomb Incorporated |
COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
|
|
US7842714B2
(en)
|
2008-03-03 |
2010-11-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating ocular pain
|
|
US9192571B2
(en)
*
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
|
EP3584237B1
(en)
|
2009-10-06 |
2020-12-09 |
Allergan, Inc. |
Alpha adrenergic receptor modulators
|
|
EP2329849B1
(en)
|
2009-11-18 |
2015-04-29 |
Galderma Research & Development |
Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
|
|
US8394800B2
(en)
|
2009-11-19 |
2013-03-12 |
Galderma Laboratories, L.P. |
Method for treating psoriasis
|
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
|
RU2535008C2
(ru)
|
2010-03-26 |
2014-12-10 |
Галдерма Ресерч Энд Девелопмент |
Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
|
|
BR112012024289A2
(pt)
|
2010-03-26 |
2017-07-18 |
Galderma Res & Dev |
"método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
|
|
KR20130092957A
(ko)
|
2010-04-07 |
2013-08-21 |
알러간, 인코포레이티드 |
안과용 처방용 보존제 조성물의 조합
|
|
KR20130041803A
(ko)
|
2010-04-07 |
2013-04-25 |
알러간, 인코포레이티드 |
안과 조성물을 위한 보존제의 조합
|
|
PL2598119T3
(pl)
|
2010-07-29 |
2019-03-29 |
Allergan, Inc. |
Niezawierające konserwantów roztwory brymonidyny i timololu
|
|
BR112013009578B1
(pt)
|
2010-10-21 |
2020-10-20 |
Galderma S.A. |
composição tópica em gel e uso de uma composição tópica em gel
|
|
US8053427B1
(en)
|
2010-10-21 |
2011-11-08 |
Galderma R&D SNC |
Brimonidine gel composition
|
|
EP2736902A1
(en)
*
|
2011-07-25 |
2014-06-04 |
Allergan, Inc. |
N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
|
|
GR1009419B
(el)
|
2017-11-07 |
2018-12-14 |
Φαρματεν Αβεε |
Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
|